C4 Therapeutics, Inc.
CCCC
$2.53
-$0.08-3.07%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -26.02M | -26.32M | -34.57M | -24.67M | -17.72M |
| Total Depreciation and Amortization | 615.00K | 456.00K | 480.00K | 442.00K | 448.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 6.10M | 6.40M | 8.74M | 9.09M | 6.43M |
| Change in Net Operating Assets | 7.25M | -13.82M | 7.42M | -9.00M | 5.87M |
| Cash from Operations | -12.06M | -33.29M | -17.93M | -24.13M | -4.97M |
| Capital Expenditure | -185.00K | -- | 4.00K | 13.00K | -197.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 39.11M | 29.13M | 13.67M | 149.00K | -11.51M |
| Cash from Investing | 38.92M | 29.13M | 13.67M | 162.00K | -11.71M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | 111.00K | 10.29M | 135.00K |
| Repurchase of Common Stock | 0.00 | -155.00K | 0.00 | -85.00K | 0.00 |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | 109.00K | 1.00K | 297.00K | 0.00 |
| Cash from Financing | 0.00 | -46.00K | 112.00K | 10.51M | 135.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 26.86M | -4.21M | -4.15M | -13.47M | -16.55M |